Lead Product(s) : Lingdolinurad
Therapeutic Area : Rheumatology
Study Phase : Phase II/ Phase III
Sponsor : China Medical System Holdings
Deal Size : Undisclosed
Deal Type : Collaboration
Atom, CMS Partner on Lingdolinurad for Gout, Hyperuricemia Treatment
Details : The collaboration aims for the commercialization of ABP-671 (lingdolinurad), a novel oral small molecule URAT1 inhibitor for the treatment of chronic gout and hyperuricemia.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Lingdolinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase II/ Phase III
Sponsor : China Medical System Holdings
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?